Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1,059 Mln
P/E Ratio
191.5
P/B Ratio
2.82
Industry P/E
--
Debt to Equity
0.21
ROE
0.02 %
ROCE
1.23 %
Div. Yield
0 %
Book Value
2.56
EPS
0.04
CFO
$-550.16 Mln
EBITDA
$-666.04 Mln
Net Profit
$-787.15 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Aurinia Pharmaceuticals (AUPH)
| -11.02 | -5.33 | -0.50 | 56.97 | -9.61 | -12.80 | 7.16 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Aurinia Pharmaceuticals (AUPH)
| 108.10 | -81.11 | 65.37 | -31.74 | 197.07 | 50.22 | 115.71 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.57 | 730.07 | -- | -14.75 | |
| 4.13 | 151.28 | -- | -53.27 | |
| 3.00 | 90.55 | -- | -19.21 | |
| 37.46 | 2,687.42 | -- | -27.85 |
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult... patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. Address: #140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6 Read more
President, CEO & Director
Mr. Peter S. Greenleaf M.B.A.
President, CEO & Director
Mr. Peter S. Greenleaf M.B.A.
Headquarters
Edmonton, AB
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aurinia Pharmaceuticals Inc (AUPH) stood at $ 551 Mln as on 31-Dec-24
The share price of Aurinia Pharmaceuticals Inc (AUPH) is $7.99 (NASDAQ) as of 24-Apr-2025 12:43 EDT. Aurinia Pharmaceuticals Inc (AUPH) has given a return of -9.61% in the last 3 years.
Aurinia Pharmaceuticals Inc (AUPH) has a market capitalisation of $ 1,059 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Aurinia Pharmaceuticals Inc (AUPH) is 191.50 times as on 22-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aurinia Pharmaceuticals Inc (AUPH) and enter the required number of quantities and click on buy to purchase the shares of Aurinia Pharmaceuticals Inc (AUPH).
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. Address: #140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6
The CEO & director of Mr. Peter S. Greenleaf M.B.A.. is Aurinia Pharmaceuticals Inc (AUPH), and CFO & Sr. VP is Mr. Peter S. Greenleaf M.B.A..
There is no promoter pledging in Aurinia Pharmaceuticals Inc (AUPH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
328
|
|
|
86
|
|
|
23
|
|
|
22
|
| Aurinia Pharmaceuticals Inc (AUPH) | Ratios |
|---|---|
|
Return on equity(%)
|
1.52
|
|
Operating margin(%)
|
5.22
|
|
Net Margin(%)
|
2.45
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aurinia Pharmaceuticals Inc (AUPH) was $0 Mln.
$-0.10
(
